
Supernus Pharmaceuticals (SUPN) Stock Forecast & Price Target
Supernus Pharmaceuticals (SUPN) Analyst Ratings
Bulls say
Supernus Pharmaceuticals Inc. is positioned positively due to its strong portfolio in the central nervous system therapeutics market, particularly highlighted by the anticipated growth of Qelbree, which is projected to achieve sales exceeding $600 million, bolstered by a new patent extension protecting it until 2035. The company benefits from a robust balance sheet that affords it the ability to pursue strategic acquisitions in the range of $500 million to $1.5 billion, potentially enhancing its market offerings. Furthermore, with a patient satisfaction rate of approximately 80% for Qelbree and a strong commercial presence, Supernus is well-positioned to leverage these factors for continued growth and expansion.
Bears say
Supernus Pharmaceuticals Inc has experienced a negative outlook due to the downgrade following disappointing Phase 2b data from its SPN-820 treatment for treatment-resistant depression. The company's potential market growth may be further diluted by commercial execution failures and the inherent risks associated with clinical trials, which could result in unfavorable outcomes. Additionally, the possibility of failing to secure regulatory approval for new or expanded indications may limit the adoption of Supernus' existing products among clinicians who may prefer established therapies.
This aggregate rating is based on analysts' research of Supernus Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Supernus Pharmaceuticals (SUPN) Analyst Forecast & Price Prediction
Start investing in Supernus Pharmaceuticals (SUPN)
Order type
Buy in
Order amount
Est. shares
0 shares